Company Summary - Lipoxen PLC (LSE:LPX)
10.25p
0.00p
FTSE AIM All Share Pharmaceuticals & BiotechnologyMarket cap: £12.285m
Review a company's summary page in more detail and see the key fundamentals at a glance. Sign-up to Premium now to make your investment decisions.
Sign-up to Premium's Free 7 Day trial See an improved company summary
Summary
Development of drug and Vaccine delivery systems and proprietary products in the fields of protein drugs, vaccines and oncology
| Financials - Interim (31/7/2008) | ||
|---|---|---|
| Turnover | £m | 0.42 |
| Pre-tax Profit | £m | -1.96 |
| EPS | p | -1.51 |
| DPS | p | 0.00 |
| Director | Board Role |
|---|---|
| Sir Brian Richards | Chairman |
| Colin Hill | Finance Director |
| Scott Maguire | Chief Executive |
Products Brands & Subsidiaries
Products & Brands
There are no products for this company.
Subsidiaries
Lipoxen Technologies Ltd
Free Annual Reports
The PrecisionIR Group Annual Reports Service provides you with quick access to annual reports and other information on selected companies.
Broker Sentiment (1 brokers)
Strong SellStrong Buy
| Heading | Date |
|---|---|
| Change of Adviser | 14/11/2008 |
| Director/PDMR Shareholding and ... | 31/10/2008 |
| Additional Listing | 17/10/2008 |